Next Article in Journal
Asthma and Chronic Rhinosinusitis: How Similar Are They in Pathogenesis and Treatment Responses?
Next Article in Special Issue
EnvIRONmental Aspects in Myelodysplastic Syndrome
Previous Article in Journal
Pseudomonas Flagella: Generalities and Specificities
Previous Article in Special Issue
Effect of 8-Day Fasting on Leukocytes Expression of Genes and Proteins Involved in Iron Metabolism in Healthy Men
Review

Is Chelation Therapy a Potential Treatment for Parkinson’s Disease?

1
Centre for Neurodegeneration and Neuroinflammation, Division of Brain Sciences, Department of Medicine, Imperial College, London W12 0NN, UK
2
Parkinson’s UK. 15 Vauxhall Bridge Road, London SW1V 1EJ, UK
3
Department of Neurology and Neurosciences, Clínica Universidad de Navarra, Pamplona, 28027 Madrid, Spain
4
Faculty of Science, Universite de Catholique de Louvain, 1348 Louvain-la-Neuve, Belgium
*
Author to whom correspondence should be addressed.
Academic Editor: Cesar Borlongan
Int. J. Mol. Sci. 2021, 22(7), 3338; https://doi.org/10.3390/ijms22073338
Received: 15 January 2021 / Revised: 25 February 2021 / Accepted: 6 March 2021 / Published: 24 March 2021
Iron loading in some brain regions occurs in Parkinson’s Disease (PD), and it has been considered that its removal by iron chelators could be an appropriate therapeutic approach. Since neuroinflammation with microgliosis is also a common feature of PD, it is possible that iron is sequestered within cells as a result of the “anaemia of chronic disease” and remains unavailable to the chelator. In this review, the extent of neuroinflammation in PD is discussed together with the role played by glia cells, specifically microglia and astrocytes, in controlling iron metabolism during inflammation, together with the results of MRI studies. The current use of chelators in clinical medicine is presented together with a discussion of two clinical trials of PD patients where an iron chelator was administered and showed encouraging results. It is proposed that the use of anti-inflammatory drugs combined with an iron chelator might be a better approach to increase chelator efficacy. View Full-Text
Keywords: iron; chelators; Parkinson’s disease; neuroinflammation iron; chelators; Parkinson’s disease; neuroinflammation
Show Figures

Figure 1

MDPI and ACS Style

Ward, R.J.; Dexter, D.T.; Martin-Bastida, A.; Crichton, R.R. Is Chelation Therapy a Potential Treatment for Parkinson’s Disease? Int. J. Mol. Sci. 2021, 22, 3338. https://doi.org/10.3390/ijms22073338

AMA Style

Ward RJ, Dexter DT, Martin-Bastida A, Crichton RR. Is Chelation Therapy a Potential Treatment for Parkinson’s Disease? International Journal of Molecular Sciences. 2021; 22(7):3338. https://doi.org/10.3390/ijms22073338

Chicago/Turabian Style

Ward, Roberta J., David T. Dexter, Antonio Martin-Bastida, and Robert R. Crichton 2021. "Is Chelation Therapy a Potential Treatment for Parkinson’s Disease?" International Journal of Molecular Sciences 22, no. 7: 3338. https://doi.org/10.3390/ijms22073338

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop